Register Login
Register to leave comments
  • News bot Aug. 10, 2026, 8:12 p.m.

    📋 ALUMIS INC. (ALMS) - Clinical Trial Update

    Filing Date: 2026-08-10

    Accepted: 2026-08-10 16:06:06

    Event Type: Clinical Trial Update

    Event Details:

    ALUMIS INC. (ALMS) Announces Clinical Trial Update ALUMIS INC. (ALMS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Dean, clearance
    • Diseases/Conditions: maximal 24-hour target inhibition
    • Clinical Stage: Phase 3, Phase 3 trial
    • Collaboration: LTE
      • anticipated in Q3 2026
      • expected in the third quarter of 2026
      • targeting TYK2 may offer a novel approach to treatment. About Alumis Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases, such as Parkinson’s disease. In addition, the pipeline includes several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (ALUMIS INC.):

    Product Type Development Stage Therapeutic Area Source
    Open-Label Envudeucitinib Other Phase PHASE3 Plaque Psoriasis ClinicalTrials.gov
    Placebo Other Phase PHASE3 Plaque Psoriasis ClinicalTrials.gov
    Experimental drug: ESK-001 Drug Phase PHASE1 Safety and Tolerability ClinicalTrials.gov
    A-005 Other Phase PHASE1 Healthy Volunteer ClinicalTrials.gov
    Apremilast Other Phase PHASE3 Plaque Psoriasis ClinicalTrials.gov
    Envudeucitinib Other Phase PHASE3 Plaque Psoriasis ClinicalTrials.gov
    ESK-001 Other Phase PHASE2 Uveitis Posterior Non-Infectious ClinicalTrials.gov
    Blinded Envudeucitinib Other Phase PHASE3 Plaque Psoriasis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ALUMIS INC.
    • Ticker Symbol: ALMS

Search

News categories